Shares of medical technology diabetes stocks are in the spotlight after Eli Lilly (LLY) said its weight loss drug cut the risk of developing Type 2 diabetes by 94% in in prediabetic adults who were overweight or obese after three years of weekly injections. Commenting on the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3972513/-Street-analysts-say-diabetes-stocks-overreacting-to-Lilly-GLP-study-results)
previous post